Lobbying return by Responsible Vaping Ireland
Budgetary mattersTo raise awareness of the need for resources for enforcement, surveys of the illicit vaping market and a small excise duty
Politician · Senator · 27th Seanad
Returns filed on the Register of Lobbying, newest first, with the policy area and intended results as the lobbyist published them.
To raise awareness of the need for resources for enforcement, surveys of the illicit vaping market and a small excise duty
To ensure adequate new development funding in the health budget to cover reimbursement of newly approved treatments for Irish patients in 2025.
Targeted supports for independent SME grocery/convenience stores including reduced PRSI rates; new employment subsidy scheme for full-time students employed part time in shops; extension of ICOB scheme to all town centre food businesses; VAT reduction; defer additional…
Published name "RGDATA" has no legal form. "RGDATA COMPANY LIMITED BY GUARANTEE" (CRO 104445) is the only CRO company with that name plus any legal form (Limited, DAC, UC, CLG, PLC or Teoranta). Confirm against the CRO record before relying on it.
Priorities for Shine to be considered (and included) in Budget 2025.
To ensure adequate funding for new medicines reimbursements in 2024 and 2025.
To ensure adequate funds were set aside in Budget 24 to meet the needs of people with a disability::To ensure that organisations providing services to people with a disability are funded to meet meet the needs of its service users::Pay parity and equality for staff in S39…
Delivery on SIPTU Budget 2024 priorities including Government investment in the pay and conditions of employment for the Early Years workforce
Highlight needs of asthma patients - enhanced healthcare services
Published name "The Asthma Society of Ireland" equals CRO name "ASTHMA SOCIETY OF IRELAND" (CRO 57125) after normalising legal forms such as Ltd = Limited. No other CRO company has this name. Names can be shared, so compare the address and dates on the CRO record.
To ensure adequate funding for reimbursement of newly approved medicines for Irish patients in 2024.